NERx 329
Alternative Names: NERx-329Latest Information Update: 16 Jan 2025
Price :
$50 *
At a glance
- Originator Indiana University School of Medicine
- Developer NERx Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Replication protein A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 16 Jan 2025 Indiana University School of Medicine has a patent protection for NERx 329 in the World
- 23 Oct 2024 Preclinical trials in Cancer in USA (unspecified route) before October 2024
- 23 Oct 2024 Pharmacodynamics data from a preclinical trial in Cancer presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2024)